Breaking news on cholesterol
Health Care Partnership Examined In Canadian Medical Association Journal published
Tue, 09 Mar 2010 05:00:00 PST
A research team from the Laval Centre de sante et de services sociaux, Universite de Montreal and McGill University Health Centre has examined the benefits of greater collaboration between family physicians and community pharmacists for select patients...
Obesity As Protection Against Metabolic Syndrome, Not Its Cause published
Tue, 09 Mar 2010 02:00:00 PST
The collection of symptoms that is the metabolic syndrome - insulin resistance, high cholesterol, fatty liver, and a greater risk for diabetes, heart disease, and stroke - are all related to obesity, but, according to a review in the March 9th issue of the Cell Press publication Trends in Endocrinology and Metabolism, not in the way you probably think they are...
New Report Warns: If You Take Simvastatin To Control Cholesterol, Watch Out For Infection published
Tue, 02 Mar 2010 05:00:00 PST
Simvastatin might help us control our cholesterol, but when it comes to infection, it's an entirely different story says a new research study published in the Journal of Leukocyte Biology (http://www.jleukbio.org). In the research report, scientists from Italy show that simvastatin delivers a one-two punch to the immune system...
Mipomersen Phase 3 Study In Patients With Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint published
Fri, 12 Feb 2010 00:00:00 PST
Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo...
FDA Approves New Indication For Crestor published
Wed, 10 Feb 2010 04:00:00 PST
On Feb. 8 the U.S. Food and Drug Administration approved the cholesterol-lowering medication Crestor (rosuvastatin) for some patients who are at increased risk of heart disease but have not been diagnosed with it...
Butter Leads To Lower Blood Fats Than Olive Oil published
Wed, 10 Feb 2010 02:00:00 PST
High blood fat levels normally raise the cholesterol values in the blood, which in turn elevates the risk of atherosclerosis and heart attack. Now a new study from Lund University in Sweden shows that butter leads to considerably less elevation of blood fats after a meal compared with olive oil and a new type of canola and flaxseed oil...
Mizzou Scientist Creates A Chicken Substitute, Providing A Low-Cost, Tasty Way To Add Soy To The Diet published
Fri, 05 Feb 2010 05:00:00 PST
Sure, some delicacies might taste just like chicken, but they usually feel and look much different. Soy meat alternatives, such as the soy burger, have become more popular recently, with increased sales of eight percent from 2007 to 2008. Now, scientists at the University of Missouri have created a soy substitute for chicken that is much like the real thing...
In Light Of Research About Teens' Heart Disease Risk, Lifestyle Changes Critical published
Thu, 04 Feb 2010 00:00:00 PST
Pamphlets detailing the warning signs associated with heart disease may soon end up in an unexpected location: your child's pediatrician's office. According to new research from the Centers for Disease Control and Prevention (CDC), one in five American teens has at least one risk factor for developing heart disease in adulthood...
Cholesterol's Link To Heart Disease Gets Clearer - And More Complicated published
Wed, 03 Feb 2010 04:00:00 PST
By considering molecular-level events on a broader scale, researchers now have a clearer, if more complicated, picture of how one class of immune cells goes wrong when loaded with cholesterol...
Siemens Introduces Cholesterol To The ADVIA Chemistry Concentrated Reagents Portfolio published
Fri, 29 Jan 2010 14:00:00 PST
Siemens Healthcare Diagnostics has introduced concentrated Cholesterol, the 15th ADVIAŽ Chemistry reagent in concentrated format. ADVIA Chemistry concentrated reagents offer up to 3060 tests per wedge, whilst still giving identical results to the conventional ADVIA non-concentrated reagents...
Pomegranate Extract Stimulates Uterine Contractions published
Thu, 28 Jan 2010 04:00:00 PST
The team identified beta-sitosterol - a steroid that can inhibit the absorption of cholesterol in the intestine - as the main constituent of pomegranate seed extract. The research suggests that pomegranate extract could be used as a natural stimulant to encourage the uterus to contract during labour...
Even Younger People Should Consider Cholesterol Screening published
Sun, 24 Jan 2010 01:00:00 PST
If you think heart disease is a disease of the middle aged, think again. Experts recommend that cholesterol screening should begin as early as 20 years of age because it is a key indicator of heart-attack risk, and should be rechecked at least once every five years. Atherosclerosis begins early, says Dr...
Research Published By Standard Process Inc. Scientists About The Effects Of Dietary Intervention On Cholesterol Levels published
Tue, 19 Jan 2010 06:00:00 PST
In collaboration with the scientists in the Department of Animal Sciences at the University of Wisconsin-Madison, Standard Process scientists have published a study examining the effects of nutritional supplement ingredients on cholesterol levels in Rapacz familial hypercholesterolemic swine or FH swine. Findings of this study were reported in the Journal of Medicinal Food...
Higher Statin Doses Not Always Best At Preventing Coronary Artery Disease published
Tue, 19 Jan 2010 02:00:00 PST
Statins have proven highly effective at lowering cholesterol. Typically, a treat-to-target approach, which means treating to a target cholesterol level, is taken with statin therapy. However, some experts believe that a tailored approach that uses different dosages based on pateints' risk for cardiovascular disease may be a better strategy for reducing the risk of coronary artery disease...
Treat The Risk, Not The Cholesterol: Study Challenges Current Cholesterol Recommendations published
Tue, 19 Jan 2010 01:00:00 PST
A new study by the University of Michigan Medical School and VA Ann Arbor Health System challenges the medical thinking that the lower the cholesterol, the better...
Impax Laboratories Confirms Patent Challenge Relating To WELCHOL(R) 625 Mg Tablets published
Mon, 18 Jan 2010 04:00:00 PST
Impax Laboratories, Inc. (NASDAQ:IPXL) confirms that it has initiated a challenge of patents listed by Daiichi Sankyo, Inc. in connection with its WELCHOLŽ (Colesevelam HCl) tablets, 625 mg. Impax filed its Abbreviated New Drug Application ("ANDA") containing a paragraph IV certification for a generic version of WELCHOLŽ with the U.S. Food & Drug Administration ("FDA")...
Despite FDA Warnings, The Monitoring Of High-Risk Medications Remains Unchanged published
Wed, 13 Jan 2010 05:00:00 PST
A new study concludes that many doctors appear to have largely ignored a Food and Drug Administration warning to screen users of new antipsychotic drugs for high blood sugar and cholesterol, which poses risks to their health and raises questions about the efficacy of warning protocols in general...
Amarin Corporation Announces First Patients Enrolled In Two Phase 3 Clinical Trials Assessing AMR101 For The Treatment Of Cardiovascular Disease published
Tue, 12 Jan 2010 01:00:00 PST
Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, announced that first patients were enrolled in the MARINE and ANCHOR Phase 3 clinical trials for AMR101, the Company's lead product candidate...
Tekmira Pharmaceuticals Completes ApoB SNALP Phase 1 Clinical Trial published
Fri, 08 Jan 2010 03:00:00 PST
Tekmira Pharmaceuticals Corporation (TSX:TKM) announced that it has concluded its ApoB SNALP Phase 1 human clinical trial. ApoB SNALP is designed to reduce the production of apolipoprotein B (ApoB), a protein produced in the liver that plays a central role in cholesterol metabolism. Tekmira enrolled a total of 23 subjects in its Phase 1 clinical trial...
Good Cholesterol Not As Protective In People With Type 2 Diabetes published
Wed, 23 Dec 2009 01:00:00 PST
High-density lipoprotein (HDL), known as "good" cholesterol, isn't as protective for people with type 2 diabetes, according to research reported in Circulation: Journal of the American Heart Association. HDL carries cholesterol out of the arteries, and high levels are associated with a lower risk of heart disease...
Low CETP Activity Associated With Heart Disease Risk published
Tue, 15 Dec 2009 18:00:00 PST
Although seen as a potential heart disease therapy, raising high-density lipoprotein (HDL) cholesterol levels by inhibiting activity of a transfer protein may not be effective, a new study suggests...
Modifiable Risk Factors For Heart Disease Identified By New Research published
Mon, 14 Dec 2009 01:00:00 PST
Special issue focuses on cardiovascular disease prevention and outcomes Emerging research on cardiovascular risk factors and treatment effects are helping clinicians gain a better understanding of which patients are most likely to benefit from close monitoring, lifestyle changes and/or additional therapeutic interventions...
Patients With High CRP And Normal LDL Have Long-Term Risk For Heart Disease, Stroke And Death published
Sun, 13 Dec 2009 00:00:00 PST
New research shows a long-term benefit in screening people for CRP, a marker for inflammation, even if they have normal levels of bad cholesterol, because of increased long-term risk for heart attack, stroke and death...
Abbott Seeks FDA Approval Of New Dosage Strengths Of SIMCORŽ (niacin Extended-release/simvastatin) published
Sat, 12 Dec 2009 01:00:00 PST
Abbott has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for two new dosage strengths of SIMCORŽ, a cholesterol medication. SIMCOR is a fixed-dose combination of niacin extended-release and simvastatin...
University Of Texas Southwestern Medical Center Researcher Wins Avanti Award In Lipids published
Sat, 12 Dec 2009 00:00:00 PST
The 2010 Avanti Award in Lipids, which recognizes outstanding research contributions in the area of lipid research, has been awarded to David W. Russell, the Eugene McDermott distinguished chair of molecular genetics at the University of Texas Southwestern Medical Center at Dallas...
)
|
|
